Nuvation Bio Inc
NYSE:NUVB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fnac Darty SA
PAR:FNAC
|
FR |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-9.13 (278% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.8 | $5.13 |
0%
|
| Industry Average | 12.1 | $-9.13 |
-278%
|
| Country Average | 19.6 | $-14.82 |
-389%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Nuvation Bio Inc
NYSE:NUVB
|
1.8B USD | -6.8 | -8.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
870.6B USD | 30.4 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.4B USD | 21.6 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.7 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
279.4B USD | 11.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.3 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 10 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Nuvation Bio Inc
Glance View
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 64 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The firm is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. The company is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.
